Attached files
| file | filename |
|---|---|
| 8-K - 8-K - SUPERNUS PHARMACEUTICALS, INC. | a18-37167_18k.htm |
Supernus to Host Third Quarter 2018 Earnings Conference Call
ROCKVILLE, Md., October 24, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial results for the third quarter of 2018 after 5:00 p.m. ET on Tuesday, November 6, 2018.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the third quarter 2018 business results on Wednesday, November 7, 2018 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
|
Conference dial-in: |
(877) 288-1043 |
|
International dial-in: |
(970) 315-0267 |
|
Conference ID: |
2697616 |
|
Conference Call Name: |
Supernus Pharmaceuticals Third Quarter 2018 Earnings |
|
|
Conference Call |
Following the live call, a replay will be available on the Company’s website under the ‘Investors’ section. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD, and Oxtellar XR for the treatment of bipolar.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com